Actively Recruiting
Phase II Study of Anlotinib Combined With Benmelstobart and Hepatic Arterial Infusion Chemotherapy for First-Line Treatment of Unresectable Liver Cancer
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-09-08
30
Participants Needed
1
Research Sites
16 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of combining anlotinib with benmelstobart and hepatic arterial infusion chemotherapy HAIC as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma uHCC who meet specific diagnostic criteria and have not received prior systemic therapy. This phase II, single-arm, multicenter exploratory clinical study aims to provide new insights into treatment options for this condition. Participants receive HAIC using the FOLFOX regimen every 3 weeks for up to 6 cycles. They also take oral anlotinib 10 mg on days 1 to 14 and receive intravenous benmelstobart 1200 mg on day 1 of each 21-day cycle. Treatment continues for up to 2 years or until disease progression, unacceptable toxicity, successful surgical conversion, or other reasons for stopping treatment occur. Throughout the study, participants undergo assessments including imaging scans to measure tumor response, blood tests, and monitoring for side effects. Researchers track outcomes such as objective response rate, progression-free survival, overall survival, disease control rate, duration of response, surgical conversion rate, and changes in specific biomarkers. The study plans to enroll 30 patients and monitor them for up to 24 months, with safety and efficacy evaluations conducted regularly during treatment.
CONDITIONS
Brief Title
Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
Research Team
C
Changzhen Shang, M.D, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here